In HNSCC, several studies have demonstrated that IL-33 may favor tumor progression by promoting tumor aggressiveness, angiogenesis or modulation of the tumor immune microenvironment (TIME) (21–24). Here, IL33 is linked to head and neck squamous cell carcinoma.